Biotech Investment Group Announced Today the Promotion of Cyrus K. Mirsaidi to the Board of Directors of Molecular Response as Vice Chairman, and His New Appointment as President and CEO of Formex

SAN DIEGO, Feb. 17, 2015 /PRNewswire/ -- Biotech Investment Group (BIG), a privately held investment fund and provider of growth capital to emerging healthcare services companies, announced today the appointment of Cyrus K. Mirsaidi, to President and CEO of Formex, LLC.  Formex is a BIG portfolio company, and

a leader in pharmaceutical API formulation, development and cGMP manufacturing, with a turnkey 40,000 sf manufacturing facility in Torrey Pines, San Diego.  Mr. Mirsaidi, who has served as CEO of Molecular Response, LLC (MRL), a San Diego-based translational oncology services company from its inception in 2010, will continue to serve on its board as Vice Chairman and acting CEO.  Molecular Response will continue to work closely with pharmaceutical partners. 

Mr. Mirsaidi will directly report to Dr. Masood Tayebi, the Chairman of the Board for both BIG and Formex.  Mr. Mirsaidi will lead Formex's overall strategy and more specifically focus on corporate expansion, process improvements and excellence across all operational areas.

"Cyrus has been a key contributor to BIG portfolio companies for several years, and has proven himself as a strong and capable leader," said Chairman, Dr. Masood Tayebi. "At BIG, we are focused on identifying healthcare companies in need of growth capital and management expertise.  Cyrus' leadership of Formex will build on the current platform and established expertise in formulation and analytical development and enable BIG to realize the full potential of unique cGMP offerings in pre-clinical to phase 3 drug development and manufacturing."

Mr. Mirsaidi brings both practical and strategic senior management experience for young start-ups to fortune 100 companies, with a proven track record from FDA regulated clinical diagnostics to high throughput compound library synthesis and purification, and from pre-clinical drug development, to clinical programs for targeted therapeutics in translational oncology. He held several senior level management positions in his ten-year career at Nichols Institute Diagnostics (a division of Quest Diagnostics), where he was responsible for global launch of FDA regulated, clinical diagnostic IVD tests and automated platforms. As general manager and executive director at Ontogen, a small molecule discovery company, he managed operations of a subsidiary focused on high throughput synthesis and purification of novel chemical compounds. Mr. Mirsaidi served as Vice President at AltheaDx, a spin-out from Althea Technologies, a San Diego biologics GMP manufacturing company, and most recently served as CEO and founder of Molecular Response, LLC, a CRO focused on translational oncology.

About Biotech Investment Group

Biotech Investment Group (BIG), founded in 2006, is a provider of growth capital to emerging healthcare services companies. Our mission is to partner with outstanding entrepreneurs to build long lasting companies and deliver services that address significant unmet healthcare needs.  BIG is known for its highly experienced investment team, with considerable breadth of healthcare industry and investment experience and an outstanding network of contacts. Our team expertise ranges from early stage drug discovery to late stage product development and launch, industry operating experience, and business development.

For additional information, please visit www.bioinv.com

About Formex LLC

Formex LLC ("Formex"), The Formulation Experts, is a leading contract development and manufacturing organization focusing on oral and topical dosage forms. Formex specializes in bioavailability enhancement and controlled release technologies, such as hot melt extrusion, spray drying, fluid bed processing, and liquid/semi-solid filled hard capsules.

For further information please visit our website: www.formexllc.com

 

SOURCE Molecular Response

← Back